444 results on '"Riganti C"'
Search Results
2. Exploring the mechanisms of metabolic adaptations to cardiotoxic doxorubicin
3. Selective delivery of pentamidine toward cancer cells by self-assembled nanoparticles
4. Cardiometabolic rewiring in the context of doxorubicin-induced cardiotoxicity: fuel preference changes from fatty acids to glucose oxidation
5. Tuning of surface chemical and optical properties of nanodiamonds for biosensing and drug delivery applications
6. In-Hospital Cardiac Arrest: How to Improve Survival?
7. Hazards assessment of micro- and nanoplastics and associated additives/contaminants to human health
8. BLSD Prevention of Sudden Death: What Is the Difference Between Lay People and Medical Professionals?
9. In-Hospital Cardiac Arrest: Are We Well Enough Equipped and Prepared to Face It?
10. IMMUNE SUPPRESSION OF BONE MARROW Vγ9Vδ2 T CELLS BY BONE MARROW STROMAL CELLS (BMSC) IN MULTIPLE MYELOMA
11. Sdox, a H2S releasing anthracycline, with a safer profile than doxorubicin toward vasculature
12. A diabetic milieu promotes OCT4 and NANOG production in human visceral-derived adipose stem cells
13. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells
14. Digoxin and ouabain increase the synthesis of cholesterol in human liver cells
15. PACEMAKER AND IMPLANTED CARDIOVERTER DEFIBRILLATOR WITHOUT REVERSAL OF DOAC THERAPY
16. Sphingolipid synthesis inhibition by myriocin administration enhances lipid consumption and ameliorates lipid response to myocardial ischemia reperfusion injury
17. BARRIER AND FACILITATORS TO PUBLIC ACCESS DEFIBRILLATION IN OUT OF HOSPITAL CARDIAC ARREST: THE SORRENTO PENINSULA REGISTER
18. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
19. Mutant p53-associated molecular mechanisms of ROS regulation in cancer cells
20. Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib towards primary CLL cells
21. Mutant p53 induces SIRT3/MnSOD axis to moderate ROS production in melanoma cells
22. Mutant p53-associated molecular mechanisms of ROS regulation in cancer cells
23. HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
24. Insulin activates hypoxia-inducible factor-1α in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling
25. Omega-3 PUFA modulate p-glicoprotein (Pgp) activity altering lipid raft cholesterol: SW04.S17–22
26. The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood–brain barrier cells
27. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis
28. Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1α and P-glycoprotein overexpression
29. What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg
30. Metabolic adaptation in colorectal cancer: heme export is required for the down-modulation of the tricarboxylic acid cycle
31. The heme biosynthesis-heme export axis is required for the modulation of the tricarboxylic acid cycle
32. Correction to: Light-regulated no release as a novel strategy to overcome doxorubicin multidrug resistance (ACS Medicinal Chemistry Letters (2017) 8:3 (361-365) DOI: 10.1021/acsmedchemlett.7b00016)
33. MULTIFACETED IMMUNE CHECKPOINT EXPRESSION AND SENESCENT MARKERS IMPAIRS BONE MARROW Vγ9Vδ2 T-CELL FUNCTION IN MULTIPLE MYELOMA PATIENTS
34. GIFC-2018 - BOOK OF ABSTRACTS
35. REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET
36. The heme exporter FLVCR1a modulates the tricarboxylic acid cycle: a new target in colorectal cancer
37. SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE
38. Hazard determinants of carbon nanotubes (cnts) driving molecular initiating events (mies) in adverse outcome pathways (aops) of airways diseases
39. IH2 INHIBITION ENHANCES PROTEASOME INHIBITOR RESPONSIVENESS IN HEMATOLOGICAL MALIGNANCIES
40. TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
41. Comparison of Allogeneic and Syngeneic Rat Glioma Models by Using MRI and Histopathologic Evaluation
42. TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
43. Melusin modulates fatty acids β-oxidation and ROS production in the heart
44. 1601d Hazard determinants of carbon nanotubes (cnts) driving molecular initiating events (mies) in adverse outcome pathways (aops) of airways diseases
45. P2.09-003 Dissecting the Immune Environment in Malignant Pleural Mesothelioma: Results from a Prospective Assessment
46. FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis
47. 073_16803-M1 Heartsaver CPR AED Guidelines: A Comparison of Conventional Teaching and Peer-Led Training for High School Students
48. 073_16805-M3 Comparison of the Implantable Cardiac Monitor Reveal XT vs Reveal LINQ in Young Patient With Syncope of Uncertain Origin
49. TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
50. C/EBP-β-LIP turnover decides cancer chemotherapy outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.